Cowen restated their buy rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note published on Monday morning.

BMRN has been the subject of a number of other research reports. Cantor Fitzgerald set a $126.00 target price on BioMarin Pharmaceutical and gave the company a buy rating in a research note on Monday, October 15th. ValuEngine raised BioMarin Pharmaceutical from a hold rating to a buy rating in a research note on Wednesday, October 3rd. BidaskClub raised BioMarin Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, October 9th. Wedbush set a $120.00 target price on BioMarin Pharmaceutical and gave the company a buy rating in a research note on Thursday, September 13th. Finally, Raymond James lowered BioMarin Pharmaceutical from an outperform rating to a market perform rating and set a $83.16 target price for the company. in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $113.38.

Shares of BMRN traded down $0.40 during midday trading on Monday, reaching $93.54. The stock had a trading volume of 6,861 shares, compared to its average volume of 979,312. BioMarin Pharmaceutical has a 12-month low of $75.81 and a 12-month high of $106.74. The company has a current ratio of 2.87, a quick ratio of 2.26 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $16.18 billion, a P/E ratio of -139.56 and a beta of 1.57.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 25th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative return on equity of 2.98% and a negative net margin of 8.35%. The company had revenue of $391.71 million during the quarter, compared to analyst estimates of $369.43 million. On average, equities research analysts predict that BioMarin Pharmaceutical will post -0.13 EPS for the current year.

In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $92.15, for a total transaction of $829,350.00. Following the completion of the transaction, the executive vice president now owns 58,135 shares of the company’s stock, valued at approximately $5,357,140.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jean Jacques Bienaime sold 3,000 shares of the company’s stock in a transaction that occurred on Saturday, December 28th. The shares were sold at an average price of $84.04, for a total value of $252,120.00. Following the transaction, the chief executive officer now directly owns 291,290 shares of the company’s stock, valued at approximately $24,480,011.60. The disclosure for this sale can be found here. Insiders have sold a total of 32,150 shares of company stock valued at $2,837,490 in the last ninety days. 1.90% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc raised its position in BioMarin Pharmaceutical by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 15,004,770 shares of the biotechnology company’s stock valued at $1,455,013,000 after purchasing an additional 107,717 shares during the last quarter. Waddell & Reed Financial Inc. raised its position in shares of BioMarin Pharmaceutical by 5.0% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 3,337,346 shares of the biotechnology company’s stock worth $314,378,000 after acquiring an additional 160,247 shares in the last quarter. Capital World Investors raised its position in shares of BioMarin Pharmaceutical by 34.3% in the 3rd quarter. Capital World Investors now owns 2,461,841 shares of the biotechnology company’s stock worth $238,725,000 after acquiring an additional 628,738 shares in the last quarter. Capital International Investors bought a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth approximately $204,025,000. Finally, Frontier Capital Management Co. LLC raised its position in shares of BioMarin Pharmaceutical by 14.4% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 1,384,495 shares of the biotechnology company’s stock worth $134,254,000 after acquiring an additional 174,023 shares in the last quarter.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: Asset Allocation, Balancing Your Investments

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.